Cargando…
Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441771/ https://www.ncbi.nlm.nih.gov/pubmed/37609387 http://dx.doi.org/10.3389/fonc.2023.1232476 |
| _version_ | 1785093445600149504 |
|---|---|
| author | Lorusso, Domenica Danesi, Romano Locati, Laura Deborah Masi, Gianluca De Giorgi, Ugo Gadducci, Angiolo Pignata, Sandro Sabbatini, Roberto Savarese, Antonella Valabrega, Giorgio Zamagni, Claudio Colombo, Nicoletta |
| author_facet | Lorusso, Domenica Danesi, Romano Locati, Laura Deborah Masi, Gianluca De Giorgi, Ugo Gadducci, Angiolo Pignata, Sandro Sabbatini, Roberto Savarese, Antonella Valabrega, Giorgio Zamagni, Claudio Colombo, Nicoletta |
| author_sort | Lorusso, Domenica |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10441771 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104417712023-08-22 Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma Lorusso, Domenica Danesi, Romano Locati, Laura Deborah Masi, Gianluca De Giorgi, Ugo Gadducci, Angiolo Pignata, Sandro Sabbatini, Roberto Savarese, Antonella Valabrega, Giorgio Zamagni, Claudio Colombo, Nicoletta Front Oncol Oncology Frontiers Media S.A. 2023-08-07 /pmc/articles/PMC10441771/ /pubmed/37609387 http://dx.doi.org/10.3389/fonc.2023.1232476 Text en Copyright © 2023 Lorusso, Danesi, Locati, Masi, De Giorgi, Gadducci, Pignata, Sabbatini, Savarese, Valabrega, Zamagni and Colombo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Lorusso, Domenica Danesi, Romano Locati, Laura Deborah Masi, Gianluca De Giorgi, Ugo Gadducci, Angiolo Pignata, Sandro Sabbatini, Roberto Savarese, Antonella Valabrega, Giorgio Zamagni, Claudio Colombo, Nicoletta Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma |
| title | Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma |
| title_full | Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma |
| title_fullStr | Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma |
| title_full_unstemmed | Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma |
| title_short | Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma |
| title_sort | corrigendum: optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441771/ https://www.ncbi.nlm.nih.gov/pubmed/37609387 http://dx.doi.org/10.3389/fonc.2023.1232476 |
| work_keys_str_mv | AT lorussodomenica corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT danesiromano corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT locatilauradeborah corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT masigianluca corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT degiorgiugo corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT gadducciangiolo corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT pignatasandro corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT sabbatiniroberto corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT savareseantonella corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT valabregagiorgio corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT zamagniclaudio corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma AT colombonicoletta corrigendumoptimizingtheuseoflenvatinibincombinationwithpembrolizumabinpatientswithadvancedendometrialcarcinoma |